KRP-104 / Kyorin - LARVOL DELTA

Safety and efficacy of once-daily KRP-104 in type 2 diabetic patients that cannot control their diabetes on metformin alone (Synergy 104) (clinicaltrials.gov) - ActivX Biosciences / P2, N=400

Diabetes

KRP-104, a uniquely prandial-targeted DPP4 inhibitor (EASD 2012) - Publication-only abstract: P2, N=403; NCT00525330, NCT00995345; P1b KRP vs Sita. Group1: KRP at 80mg twice daily produced Con-inh of ~90-95% and glycemic efficacy similar to sita at =>80% Con-inh assessed by fasting plasma glucose (FPG), 7 point glucose (G), or Con G monitoring; No increase in glycemic effect was seen with higher inh; Group2: Prand-only inhibition by KRP (70mg) achieved comparable glycemic efficacy to sita; P2a Diurnal Profile Assessment: KRP 120mg once daily (prand-inh); 60mg twice daily (=>80% Con-inh).

P2 data • Diabetes